THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

There's no shortage of cancer immunotherapies ... Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination ...

Libtayo plus chemotherapy increased median overall survival from 13 to 22 months in ... Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal ...

In that case, three types of immunotherapy can be used, which include the following medications: pembrolizumab (Keytruda®), atezolizumab (Tecentriq®), and cemiplimab (Libtayo ... improvement in ...

In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...

Adam Schefter announces the news, celebrating Moss as a cancer survivor and welcoming him back to the show airing live from New Orleans this Sunday. “A huge welcome back,” shares NFL Insider ...

The first phase of construction of a Commack park dedicated to those who have survived their battle with breast cancer is ...

Brandow, who learned she had stage 4 lymphoma in 2020 after giving birth to her younger son, wants to lift barriers to health ...

There are not many programmes designed for young people living with or surviving cancer. UiA and the Hospital of Southern Norway, in collaboration with international researchers, aim to explore how ...

Lucy Notarantonio is Newsweek's Senior Lifestyle and Trends Reporter, based in Birmingham, UK. Her focus is trending stories and human interest features ranging from health, pets and travel.